Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: tsatalas k. Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420. Blood. 2015. PMID: 26359434 Free article. Clinical Trial. No abstract available.
Prognostication of the high-risk WM patient.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Michael M, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, Dimopoulos MA. Kastritis E, et al. Among authors: tsatalas k. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):127-9. doi: 10.3816/CLML.2011.n.028. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454212
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E, Kyrtsonis MC, Hatjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Michael M, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gavriatopoulou M, Koulieris E, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, Dimopoulos MA. Kastritis E, et al. Among authors: tsatalas k. Am J Hematol. 2011 Jun;86(6):479-83. doi: 10.1002/ajh.22027. Epub 2011 Apr 20. Am J Hematol. 2011. PMID: 21509798 Free article.
Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine.
Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki HA, Spanoudakis E, Tsatalas K, Kotsianidis I. Miltiades P, et al. Among authors: tsatalas k. Blood Cancer J. 2014 Feb 28;4(2):e187. doi: 10.1038/bcj.2014.9. Blood Cancer J. 2014. PMID: 24583533 Free PMC article. No abstract available.
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Matsouka P, Pagoni M, Zikos P, Giannakoulas N, Apostolidis I, Asprogeraka T, Arvanitopoulou E, Spanoudakis E, Kotsianidis I, Tsatalas K, Papaioannou M, Marinakis T, Skandali A, Viniou N, Yataganas X, Bakiri M. Matsouka P, et al. Among authors: tsatalas k. Ann Hematol. 2006 Apr;85(4):250-6. doi: 10.1007/s00277-005-0066-0. Epub 2006 Jan 14. Ann Hematol. 2006. PMID: 16416114 Clinical Trial.
12 results